AU2018217375B2 - A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings - Google Patents

A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings Download PDF

Info

Publication number
AU2018217375B2
AU2018217375B2 AU2018217375A AU2018217375A AU2018217375B2 AU 2018217375 B2 AU2018217375 B2 AU 2018217375B2 AU 2018217375 A AU2018217375 A AU 2018217375A AU 2018217375 A AU2018217375 A AU 2018217375A AU 2018217375 B2 AU2018217375 B2 AU 2018217375B2
Authority
AU
Australia
Prior art keywords
treatment
factor
product
atiii
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018217375A
Other languages
English (en)
Other versions
AU2018217375A1 (en
Inventor
Oliver GROTTKE
Eva HERZOG
Gerald HOCHLEITNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring GmbH Deutschland
Original Assignee
CSL Behring GmbH Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring GmbH Deutschland filed Critical CSL Behring GmbH Deutschland
Publication of AU2018217375A1 publication Critical patent/AU2018217375A1/en
Application granted granted Critical
Publication of AU2018217375B2 publication Critical patent/AU2018217375B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21038—Coagulation factor XIIa (3.4.21.38)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2018217375A 2017-02-09 2018-02-09 A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings Active AU2018217375B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17155420.7 2017-02-09
EP17155420 2017-02-09
PCT/EP2018/053240 WO2018146235A1 (en) 2017-02-09 2018-02-09 A blood coagulation factor replacement product for use in the treatment or prophyl of bleedings

Publications (2)

Publication Number Publication Date
AU2018217375A1 AU2018217375A1 (en) 2019-06-27
AU2018217375B2 true AU2018217375B2 (en) 2024-04-18

Family

ID=58016586

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018217375A Active AU2018217375B2 (en) 2017-02-09 2018-02-09 A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings

Country Status (13)

Country Link
US (1) US11744880B2 (cg-RX-API-DMAC10.html)
EP (1) EP3579857B1 (cg-RX-API-DMAC10.html)
JP (1) JP7227905B2 (cg-RX-API-DMAC10.html)
KR (1) KR102658958B1 (cg-RX-API-DMAC10.html)
CN (1) CN110114074B (cg-RX-API-DMAC10.html)
AU (1) AU2018217375B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019012772A2 (cg-RX-API-DMAC10.html)
CA (1) CA3046406C (cg-RX-API-DMAC10.html)
DK (1) DK3579857T3 (cg-RX-API-DMAC10.html)
ES (1) ES2913934T3 (cg-RX-API-DMAC10.html)
PL (1) PL3579857T3 (cg-RX-API-DMAC10.html)
SG (1) SG10201912497WA (cg-RX-API-DMAC10.html)
WO (1) WO2018146235A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210308228A1 (en) * 2020-04-04 2021-10-07 The Board Of Regents Of The University Of Texas System Method for reducing the occurrence of thrombosis or thromboembolism
CN113929741A (zh) * 2020-06-29 2022-01-14 首都医科大学 华法林-4-O-乙酰-Gly-Pro-Arg-Pro-AA1及其合成、活性和应用
WO2026048976A1 (ja) * 2024-08-30 2026-03-05 Ｋｍバイオロジクス株式会社 血液凝固第ｘ因子を含む安定な医薬組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663164A (en) * 1980-01-28 1987-05-05 Baxter Travenol Laboratories, Inc. Aqueous compositions for treating blood clotting factor inhibitors
DE3101752A1 (de) 1981-01-21 1982-08-26 Behringwerke Ag, 3550 Marburg "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen"
DE3336631A1 (de) * 1983-10-08 1985-04-18 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von plasma oder von konzentraten der blutgerinnungsfaktoren ii, vii, ix und x
DE3622642A1 (de) * 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
SI0796623T1 (en) * 1996-03-20 2005-10-31 Baxter Aktiengesellschaft Pharmaceutical preparation for the treatment of blood coagulation disorders
AT409334B (de) 1997-09-19 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren
CN100415093C (zh) 2003-01-27 2008-09-03 哈维斯特技术公司 从抗凝全血生产的自体或同种促凝剂
FR2946348B1 (fr) 2009-06-05 2011-08-05 Lab Francais Du Fractionnement Procede de preparation d'une composition de complexe prothrombique a haut degre de purete
DK2624859T3 (en) 2010-10-06 2017-06-06 Medimmune Ltd FACTOR II ALONE OR IN COMBINATION WITH OTHER FACTORS FOR TREATMENT OF REDUCED HEMOSTASE IN CONNECTION WITH DILUTION COAGULOPATHY
TWI653047B (zh) 2014-03-14 2019-03-11 百特製藥公司 用於在出血性病症的治療中促進止血的人類凝血酶原及活化因子x的組成物
WO2016198351A1 (en) * 2015-06-10 2016-12-15 Evonik Röhm Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Antithrombin III [Viewed on internet 14 March 2024]. , published online 15 July 2006. *
GROTTKE OLIVER: "Anesthesiology, V 122 @BULLET No 4", ANESTHESIOLOGY, 1 January 2015 (2015-01-01), pages 923 - 31, XP055389277, Retrieved from the Internet *
O. GROTTKE ET AL: BLOOD, vol. 118, no. 7, 18 August 2011 (2011-08-18), US, pages 1943 - 1951, XP055389629, ISSN: 0006-4971, DOI: 10.1182/blood-2011-03-343046 *

Also Published As

Publication number Publication date
WO2018146235A1 (en) 2018-08-16
CN110114074B (zh) 2024-05-28
CN110114074A (zh) 2019-08-09
CA3046406C (en) 2024-01-30
KR20190111912A (ko) 2019-10-02
US20190351028A1 (en) 2019-11-21
BR112019012772A2 (pt) 2019-12-10
AU2018217375A1 (en) 2019-06-27
ES2913934T3 (es) 2022-06-06
KR102658958B1 (ko) 2024-04-22
JP2020506880A (ja) 2020-03-05
WO2018146235A8 (en) 2019-05-09
CA3046406A1 (en) 2018-08-16
DK3579857T3 (da) 2022-06-07
SG10201912497WA (en) 2020-02-27
PL3579857T3 (pl) 2022-07-25
EP3579857B1 (en) 2022-04-06
JP7227905B2 (ja) 2023-02-22
EP3579857A1 (en) 2019-12-18
US11744880B2 (en) 2023-09-05

Similar Documents

Publication Publication Date Title
Smith et al. Polyphosphate as a general procoagulant agent
KR101567762B1 (ko) Ｆｖⅲ 농축물을 포함하는 프로트롬빈 복합체 농축물의 상승적 치료 용도
US10604749B2 (en) Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
US9968662B2 (en) Factor VII composition
JP2003532684A (ja) 第ＶＩＩａ因子及びＴＦＰＩ阻害剤を含んで成る医薬組成物
US11744880B2 (en) Blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
EP2624859B1 (en) Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy
Seligsohn et al. Inherited deficiencies of coagulation factors II, V, VII, XI and XIII and the combined deficiencies of Factors V and VIII and of the Vitamin K dependent factors
Starczewska et al. Perioperative bleeding in patients undergoing liver transplantation
HK40017756A (en) A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
HK40017756B (en) A blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings
Carr Jr et al. Recombinant Factor VIIa: clinical applications for an intravenous hemostatic agent with broad-spectrum potential
Perry Factor X and Factor X deficiency
Erhardtsen et al. Recombinant Factor VIIa
JP2025522101A (ja) 止血を促進するための薬剤
WO2026048976A1 (ja) 血液凝固第ｘ因子を含む安定な医薬組成物
Lisman et al. Mechanism of action of recombinant activated Factor VII
Mammen α2-Antiplasmin Deficiency
Ranjan 1 The Rare Coagulation
HK1188391B (en) Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy
HK1188391A (en) Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)